Javascript must be enabled to continue!
Development and validation of spectroscopic simultaneous equation method for simultaneous estimation of Azelnidipine and Valsartan in synthetic mixture
View through CrossRef
A simple, specific, accurate and precise spectrophotometric method was developed and validated for simultaneous estimation of Azelnidipine and Valsartan in Synthetic Mixture. The wavelength of estimation for Azelnidipine was 240.00 nm and for Valsartan was 250.00 nm. Beer’s law is obeyed in the concentration range of 2-10μg/ml and 16-80μg/ml and correlation coefficient of 0.9999 and 0.9993 for Azelnidipine and Valsartan respectively. The % recovery for Azelnidipine and Valsartan were found to be 101.2 % - 101.9 % and 101.8 - 101.9 % respectively. Intraday precision of Azelnidipine and Valsartan were found to be 0.06 – 0.24 and 0.08 – 0.27 % RSD and Interday precision were found to be 0.14 – 0.33 and 0.11 – 0.37 % RSD respectively. The proposed method was also evaluated by the Assay of Synthetic mixture containing Azelnidipine and Valsartan. The % Assay was found to be 100.50 ± 0.002 for Azelnidipine and 100.87 ± 0.001 for Valsartan. Validation of proposed methods was carried out according to ICH Q2R1Guidelines. The proposed methods were found accurate and reproducible for routine analysis of both the drugs in synthetic mixture.
Title: Development and validation of spectroscopic simultaneous equation method for simultaneous estimation of Azelnidipine and Valsartan in synthetic mixture
Description:
A simple, specific, accurate and precise spectrophotometric method was developed and validated for simultaneous estimation of Azelnidipine and Valsartan in Synthetic Mixture.
The wavelength of estimation for Azelnidipine was 240.
00 nm and for Valsartan was 250.
00 nm.
Beer’s law is obeyed in the concentration range of 2-10μg/ml and 16-80μg/ml and correlation coefficient of 0.
9999 and 0.
9993 for Azelnidipine and Valsartan respectively.
The % recovery for Azelnidipine and Valsartan were found to be 101.
2 % - 101.
9 % and 101.
8 - 101.
9 % respectively.
Intraday precision of Azelnidipine and Valsartan were found to be 0.
06 – 0.
24 and 0.
08 – 0.
27 % RSD and Interday precision were found to be 0.
14 – 0.
33 and 0.
11 – 0.
37 % RSD respectively.
The proposed method was also evaluated by the Assay of Synthetic mixture containing Azelnidipine and Valsartan.
The % Assay was found to be 100.
50 ± 0.
002 for Azelnidipine and 100.
87 ± 0.
001 for Valsartan.
Validation of proposed methods was carried out according to ICH Q2R1Guidelines.
The proposed methods were found accurate and reproducible for routine analysis of both the drugs in synthetic mixture.
Related Results
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with...
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study
Abstract:
Nitrosamine contamination of generic valsartan was found in 2018. This study aimed to investigate whether long-term use of valsartan increases cancer risk. Pati...
Effect of valsartan and carvedilol on TNFα, IL-6 and angiotensin α on geriatric chronic heart failure
Effect of valsartan and carvedilol on TNFα, IL-6 and angiotensin α on geriatric chronic heart failure
Objective
To observe the effect of Valsartan and carvedilol on TNFα, IL-6 and angiotensin II (Ang II) in geriatric chronic heart failure (CHF).
...
Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Abstract. Sacubitril-Valsartan is a first-class therapeutic agent for ARNI (Angiotensin Receptor-Neprilysin Inhibitor) which can reduce blood pressure and reduce mortality and morb...
Validation in Doctoral Education: Exploring PhD Students’ Perceptions of Belonging to Scaffold Doctoral Identity Work
Validation in Doctoral Education: Exploring PhD Students’ Perceptions of Belonging to Scaffold Doctoral Identity Work
Aim/Purpose: The aim of this article is to make a case of the role of validation in doctoral education. The purpose is to detail findings from three studies which explore PhD stude...
GW24-e0043 Effects of valsartan on expression of gp130 in cardiac hypertrophy rat induced by Ang II
GW24-e0043 Effects of valsartan on expression of gp130 in cardiac hypertrophy rat induced by Ang II
Objectives
To observe effects of valsartan on expression of gp130 in cardiac hypertrophy rat induced by Ang II.
...
e0349 Clinical observation on different dosage of valsartan in treatment of heart failure
e0349 Clinical observation on different dosage of valsartan in treatment of heart failure
Objective
To explore the clinical value of different dosage of valsartan in treatment of chronic heartfailure (CHF).
...
P3829Antiarrhythmic effects of Sacubitrilat (LBQ657) on Ca2+ homeostasis in ventricular cardiomyocytes
P3829Antiarrhythmic effects of Sacubitrilat (LBQ657) on Ca2+ homeostasis in ventricular cardiomyocytes
Abstract
Background and objectives
Simultaneous inhibition of neprilysin and angiotensin II receptors by sacubitril/valsartan wa...

